![]() |
市场调查报告书
商品编码
1847178
全球胃肠内视镜设备市场:市场规模、份额和趋势分析(2025-2032 年)Gastrointestinal Endoscopic Device Market Size, Share & Trends Analysis | Global | 2025-2032 | Includes: GI Endoscopes, Capsule Endoscopy, Stenting and Dilation Devices, and 7 more |
||||||
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
2025 年全球胃肠内视镜设备市场价值约为 163 亿美元,预计到 2031 年将超过 215 亿美元,年复合成长率为 4.0%。
本报告涵盖胃肠内视镜、胶囊内视镜、支架置入和扩张装置、ERCP装置、切片检查钳和息肉切除勒除器、EUS穿刺针、内视镜黏膜下剥离术(ESD)刀、止血装置、经肠营养装置和反流预防装置。本研究量化了销售量、平均售价(ASP)、市场规模、成长率和企业市场占有率,并分析了手术量、成长驱动因素和限制因素、近期併购活动、产品系列和竞争格局。预测期至2031年,历史资料截至2021年。
成长的驱动因素包括筛检和早期检测项目的增加、全球人口老化以及影像处理、治疗配件、一次性平台等方面的技术升级。预计新兴地区医疗保健服务的普及将导致诊断性大肠镜检查、ERCP、EUS 和治疗性胃肠道介入等手术数量的增加。
市场概览
胃肠内视镜检查在胃肠道疾病的检测和治疗中起着至关重要的作用。大肠镜检查是大肠直肠癌筛检和息肉切除的主要手段,而上消化道内视镜检查则用于处理出血、狭窄和逆流相关疾病。诸如ERCP、ESD和EUS引导下介入等治疗性操作,已将内视镜检查的功能从诊断扩展到复杂的治疗领域。
市场价值由资本设备、可重复使用和一次性医疗器材以及大批量耗材共同驱动。资本基础包括胃肠内视镜和视讯处理器。切片检查钳、息肉切除勒除器、支架、球囊和止血装置等高通量产品类别带来持续收入。胶囊内视镜为小肠成像提供了一种非侵入性途径,而经肠营养装置则支持急性和慢性护理环境中的营养管理。
医疗机构正在从标准成像升级到高清和高清+成像,并在预算允许的情况下选择性地采用4K和放大成像技术。一次性内视镜因其在感染控制和工作流程方面的优势,在特定场所越来越受欢迎。同时,结构化的全国性筛检计画正在扩大接受胃肠道疾病诊疗的人群,从而支持该诊疗的稳定成长。
成本控制仍然是至关重要的因素。在成熟市场,集团采购组织和竞标模式正在降低平均售价,而医院预算则推动了一次性医疗器材的逐步普及。然而,随着临床医生寻求创伤较小的治疗方法开放性手术方案,以及内视镜治疗循证医学证据的不断积累,对先进治疗的需求仍在持续增长。
随着基础设施的改善、培训的普及和公众意识的提高,亚太和拉丁美洲等新兴地区预计将在全球设备销售中占据更大的份额。在这些市场,内视镜实验室和影像处理设备的成长将为诊断和治疗程序提供支援。
市场驱动因素
癌症发生率
大肠直肠癌是全球最常见的癌症之一,也是癌症相关死亡的主要原因。人口老化和公众意识的提高正在推动筛检计画的参与率不断上升。每5至10年进行一次大肠镜检查可以发现并切除癌前息肉,从而降低癌症风险。筛检参与率的提高也带动了对大肠镜、切片检查器械、勒除器和止血器械等设备的持续需求。
筛检和早期检测项目
政策调整和国家计画正在扩大筛检覆盖范围。在美国,美国预防服务工作小组(USPSTF)将大肠癌筛检的建议起始年龄从50岁降至45岁,增加了大肠镜筛检的数量。英国国民医疗服务体系(NHS)已将肠道筛检的起始年龄从60岁降至50岁。在韩国,一项国家计画每两年进行一次粪便免疫化学检测(FIT),并对阳性结果进行大肠镜检查。此类项目能够带来可预测的、规律的筛检量,支持内视镜和耗材的稳定采购,并鼓励采用能够提高息肉检出率的先进影像技术。
新技术开发
高清和高清+影像的升级,以及放大倍率和更优异的光学性能,正在提高诊断准确性。软性内视镜更易于操作,专用配件则可实现更精准的治疗。一次性使用平台降低了交叉感染的风险,并简化了再处理流程。值得关注的产品包括波士顿科学公司的Exalt Model D一次性十二指肠镜和Ambu公司的aScope系列产品。同时,3D视觉化和4K影像处理也在针对特定应用场景进行评估。随着这些技术的成熟和成本障碍的降低,预计产品销售和手术量将会增加。
新兴地区的扩张
亚太地区和拉丁美洲的医疗保健投资正在增加内视镜实验室、培训计画和转诊途径的数量。都市化和收入成长正在改善医疗保健服务的可近性。人们对胃肠道疾病的认识不断提高,筛检的普及率不断上升,推动了相关手术数量的增加,进而带动了对内视镜、ERCP设备、EUS穿刺针和止血器械的需求。
治疗范围和效率
内视镜目前可用于治疗出血、取出结石、扩张狭窄、切除早期癌症、修復缺损。拓展治疗范围将使潜在市场超越筛检和诊断的范畴。人工智慧辅助的息肉检测、改良的止血装置以及更快捷的ERCP结石处理工具将提高效率,缩短手术时间,提高手术量,从而推动内视镜技术的广泛应用。
市场限制
集团采购组织
集团采购组织 (GPO) 和竞标汇总了需求,从而压低了价格。批量承诺和积极的折扣策略有利于拥有广泛产品线的大型供应商。这些动态限制了利基市场参与者的市场准入,并压缩了平均售价 (ASP),尤其对于大规模生产的消耗品更是如此。
替代筛检
人们对侵入性较小的筛检方法越来越感兴趣,例如粪便免疫化学检测(FIT-DNA)、血液检测和胶囊内视镜检查。这些方法可以降低初次筛检的门槛。然而,即使初次筛检结果呈阳性,仍需进行大肠镜检查以确诊和治疗,内视镜检查仍将发挥核心作用。即使初次筛检在一定程度上有所改变,后续的大肠镜检查仍然必不可少,因此对大肠镜销售的影响有限。
对采用新技术犹豫不决
临床医生对采用新设备持谨慎态度。许多医疗机构希望在改变诊疗流程之前,获得确凿的临床效益和工作流程契合度证据。成本和培训时间也是阻碍设备推广的因素。例如,一次性使用平台必须透过感染控制和效率提升来证明其成本的合理性。随着时间的推移,有利的研究和更完善的采购模式可以促进设备的推广,但这需要一个循序渐进的过程。
预算限制和再加工投资
近期已投资于医疗设备再处理和设备的医院,需要明确的价值论证才会考虑改用一次性设备和高端配件。新兴地区的预算优先考虑高效益项目,这可能会延缓先进影像处理和专用工具的采用。
目标市场和数据范围
医疗机构包括医院、门诊内视镜中心、门诊手术中心和专科诊所。
目标市场及区隔
胃肠内视镜市场
胶囊内视镜市场
支架和扩张市场
内视镜逆行性胰造影(ERCP)设备市场
切片检查钳和息肉切除勒除器市场
EUS针头市场
内视镜黏膜下剥离刀市场
止血设备市场
经肠营养设备市场
回流防止装置市场
针对每个细分市场,我们分析市场价值、平均售价、销售量、成长率和企业市场占有率,提供历史趋势和到 2031 年的预测展望。
竞争分析
奥林巴斯在胃肠内视镜市场和内视镜黏膜下剥离术(ESD)刀领域保持领先地位。同时,在胶囊内视镜、ERCP器械、切片检查钳、息肉切除器、EUS穿刺勒除器和止血器械等领域也拥有较高的市占率。如此丰富的产品线确保了奥林巴斯在整体市场中的领先地位。奥林巴斯凭藉其耐用、高品质的图像、庞大的装置量以及全面的服务和培训支持,持续赢得客户的讚誉。
2025年,波士顿科学公司在众多配件类别中占据领先地位,超越其他任何竞争对手。该公司在支架置入和扩张器械、ERCP器械、切片检查钳和息肉切除勒除器、EUS穿刺针以及止血器械领域均占据领先份额,并在ESD刀领域保持着竞争优势。 AXIOS™腔内引流支架和Exalt Model D一次性十二指肠镜(解决了ERCP术后器械再处理难题)是推动公司成长的主要动力。这些产品有助于提高手术效率并控制感染,从而持续受到市场的青睐。
富士软片在胃肠内视镜市场占据第二大市场份额,整体排名第三。凭藉其强大的影像处理能力、产品可靠性和不断丰富的治疗配件产品线,富士胶片巩固了其在医院和门诊中心的地位。富士胶片的整体市占率略微超过了Avanos Medical。
其他参与企业在胶囊内视镜、经肠营养、反流预防装置等细分领域竞争。在价格敏感的地区,当地製造商提供以价值为导向的耗材,而全球领导者则在影像处理、培训和全线服务方面保持优势。
科技与临床趋势
这些趋势有助于提高内视镜实验室的吞吐量,实现更一致的结果,并治疗更广泛的疾病。
地区
其涵盖范围包括北美、欧洲、亚太地区、拉丁美洲以及中东和非洲。
胃肠内视镜设备市场中最大、成长最快的机会是什么?
筛检计划和人口老化将如何影响大肠镜检查和治疗性内视镜检查的需求。
哪些技术升级,例如一次性平台、人工智慧辅助工具和进阶影像处理,将获得市场份额?
GPO和竞标模式将如何影响大中小型製造商的定价和市场准入?
ERCP、EUS、ESD 和胶囊内视镜检查的流程预计会发生哪些变化,这些变化将如何影响辅助设备的消耗?
奥林巴斯、波士顿科学和富士胶片在资本和配件领域的定位。
哪些风险可能会减缓推广应用,例如预算限制、替代筛检以及临床医生的犹豫不决?
供应商如何调整培训、服务和库存以支持新兴地区的成长?
iData Research 的《全球胃肠内视镜设备市场报告》透过流程感知模型、定价细节和企业市场占有率分析解答了这些问题。该报告可用于量化各类别的需求、制定产品蓝图、设定定价和合约目标,以及优先进行培训和支援计划,从而加速产品推广应用。
目录
图表清单
图表列表
全球胃肠内视镜设备市场概览
竞争分析
新兴市场与技术
市场趋势
市场趋势
流程分段
市场区隔
目标区域
重要报告更新
版本历史记录
调查方法
全球关税的影响
全球胃肠内视镜设备市场概览
胃肠内视镜市场
胶囊内视镜市场
支架置入和扩张市场
经内视镜逆行性胆胰管摄影术设备市场
切片检查钳和息肉切除勒除器市场
EUS针头市场
内视镜黏膜下剥离刀市场
止血设备市场
经肠营养装置市场
回流防止装置市场
The global gastrointestinal endoscopic device market was valued at nearly $16.3 billion in 2025. It is expected to grow at a compound annual growth rate of 4.0 percent to reach over $21.5 billion by 2031.
This report covers GI endoscopes, capsule endoscopy, stenting and dilation devices, ERCP devices, biopsy forceps and polypectomy snares, EUS needles, endoscopic submucosal dissection (ESD) knives, hemostasis devices, enteral feeding devices, and anti-reflux devices. The study quantifies unit sales, average selling prices (ASPs), market size, growth rates, and company shares, and analyzes procedure volumes, growth drivers and limiters, recent mergers and acquisitions, product portfolios, and competitive dynamics. Forecasts extend to 2031 with historical data to 2021.
Growth is supported by rising screening and early detection programs, an aging global population, and technology upgrades across imaging, therapeutic accessories, and single-use platforms. As emerging regions expand healthcare access, procedure volumes are expected to increase across diagnostic colonoscopy, ERCP, EUS, and therapeutic GI interventions.
Market Overview
Gastrointestinal endoscopy is central to the detection and treatment of GI disease. Colonoscopy is the anchor procedure for colorectal cancer screening and polyp removal, while upper GI endoscopy addresses bleeding, strictures, and reflux-related pathology. Therapeutic procedures such as ERCP, ESD, and EUS-guided interventions have broadened the role of endoscopy beyond diagnosis to include complex therapy.
Market value is shaped by a mix of capital equipment, reusable and single-use devices, and high-volume consumables. The capital base includes GI endoscopes and video processors. High-throughput categories such as biopsy forceps, polypectomy snares, stents, balloons, and hemostasis tools drive recurring revenue. Capsule endoscopy adds a non-invasive pathway for small bowel imaging, while enteral feeding devices support nutrition management in acute and chronic care.
Providers are upgrading from standard imaging to HD and HD+, with selective adoption of 4K and magnification where budgets allow. Single-use endoscopes are gaining attention for infection control and workflow advantages in targeted settings. At the same time, structured national screening programs are expanding the population that enters GI care pathways, which supports steady procedure growth.
Cost control remains a defining factor. Group purchasing organizations and tender models reduce ASPs in mature markets, while hospital budgets drive staged adoption of single-use devices. Even so, demand for advanced therapy has continued to expand as clinicians pursue less invasive alternatives to open surgery and as evidence for endoscopic therapy grows.
Emerging regions in Asia-Pacific and Latin America are set to contribute a larger share of global volumes as infrastructure improves, training expands, and public awareness increases. In these markets, growth in endoscopy suites and imaging fleets will support both diagnostic and therapeutic procedures.
Market Drivers
Incidence of cancer
Colorectal cancer is one of the most common cancers worldwide and a leading cause of cancer-related death. Aging demographics and better awareness drive more people into screening programs. Colonoscopy every five to ten years allows the detection and removal of precancerous polyps, which lowers cancer risk. Rising participation in screening supports sustained demand for colonoscopes, biopsy tools, snares, and hemostasis devices.
Screening and early detection programs
Policy changes and national programs have widened the eligible screening population. In the United States, the USPSTF lowered the recommended starting age for colorectal screening from 50 to 45 years, which increases the number of screening colonoscopies. The U.K. NHS is reducing the starting age for bowel screening from 60 to 50. In South Korea, the national program uses biennial FIT with colonoscopy follow-up for positive tests. These programs create predictable, recurring volumes that support stable purchasing of scopes and consumables, and they drive adoption of higher-performance imaging to improve polyp detection.
New technological developments
Imaging upgrades to HD and HD+, along with magnification and better optics, improve diagnostic accuracy. Flexible scopes have become easier to maneuver, and specialized accessories allow more precise therapy. Single-use platforms reduce cross-contamination risk and simplify reprocessing, which can be valuable for infection control and staffing constraints. Notable products include Boston Scientific's Exalt Model D single-use duodenoscope and Ambu's aScope portfolio. In parallel, 3D visualization and 4K imaging are being evaluated for specific use cases. As these technologies mature and cost barriers decline, unit sales and procedure counts are expected to rise.
Expansion in emerging regions
Healthcare investment in Asia-Pacific and Latin America is increasing the number of endoscopy suites, training programs, and referral pathways. Urbanization and higher incomes improve access to care. As awareness of GI disease rises and screening becomes more common, procedure volumes increase, lifting demand for endoscopes, ERCP devices, EUS needles, and hemostasis tools.
Therapeutic breadth and efficiency
Endoscopy now treats bleeding, removes stones, dilates strictures, resects early cancers, and closes defects. Broader therapy expands the addressable market beyond screening and diagnosis. Efficiency gains through AI-assisted polyp detection, improved hemostasis devices, and faster ERCP stone-management tools shorten procedure time and improve throughput, which supports adoption.
Market Limiters
Group purchasing organizations
GPOs and tenders consolidate demand and push down prices, which makes it difficult for smaller manufacturers to compete. Volume commitments and aggressive discounts favor large vendors with broad portfolios. This dynamic limits the market access of niche players and compresses ASPs, particularly in high-volume consumables.
Screening alternatives
Less invasive screening methods such as FIT-DNA, blood-based tests, and capsule colonoscopy are gaining interest. These options can reduce barriers to initial screening. However, a positive result still requires a colonoscopy for confirmation and treatment, which preserves the central role of endoscopy. Even with some diversion of initial tests, downstream colonoscopy volumes remain necessary, which helps limit the impact on colonoscope unit sales.
Hesitation to adopt new technology
Clinician adoption of new devices is cautious. Many providers seek robust evidence of clinical benefit and workflow fit before changing practice. Cost and training time also slow uptake. Single-use platforms, for example, must justify expense with infection control or efficiency benefits. Over time, favorable studies and better procurement models can stimulate adoption, but the path is gradual.
Budget constraints and reprocessing investments
Hospitals with recent investments in reprocessing and capital fleets will require clear value cases to switch to single-use devices or premium accessories. Budgets in emerging regions prioritize high-impact items first, which can delay adoption of advanced imaging or specialty tools.
Market Coverage and Data Scope
Care settings include hospitals, outpatient endoscopy centers, ambulatory surgery centers, and specialty clinics.
Markets Covered and Segmentation
Gastrointestinal Endoscope Market
Capsule Endoscopy Market
Stenting and Dilation Market
Endoscopic Retrograde Cholangiopancreatography (ERCP) Device Market
Biopsy Forceps and Polypectomy Snares Market
EUS Needle Market
Endoscopic Submucosal Dissection Knife Market
Hemostasis Device Market
Enteral Feeding Device Market
Anti-Reflux Device Market
Each segment is analyzed for market values, ASPs, units, growth rates, and company shares with historical trends and forecast outlook to 2031.
Competitive Analysis
Olympus held the leading position in the GI endoscope market and in the ESD knife segment. The company also maintained strong shares in capsule endoscopy, ERCP devices, biopsy forceps, polypectomy snares, EUS needles, and hemostasis devices. This breadth secured the top overall market share. Olympus continues to benefit from a reputation for durable image quality, a large installed base, and comprehensive service and training support.
Boston Scientific led more accessory segments than any other competitor in 2025. The company held the top share in stenting and dilation devices, ERCP devices, biopsy forceps and polypectomy snares, EUS needles, and hemostasis devices, and it maintained a competitive position in ESD knives. Growth is supported by the AXIOS(TM) lumen-apposing stent for transluminal drainage and by the Exalt Model D single-use duodenoscope, which addresses reprocessing challenges in ERCP. These products help drive procedure efficiency and infection control, supporting continued adoption.
Fujifilm ranked third overall, supported by the second-largest share of the GI endoscope market. Strong imaging capabilities, product reliability, and a growing therapeutic accessory portfolio have advanced its standing in hospitals and outpatient centers. The company placed just ahead of Avanos Medical in total share.
Other participants compete across select niches such as capsule endoscopy, enteral feeding, and anti-reflux devices. In price-sensitive regions, local manufacturers supply value-oriented consumables, while global leaders retain advantages in imaging, training, and full-line service.
Technology and Practice Trends
These trends support higher throughput, more consistent outcomes, and a broader range of treatable conditions within the endoscopy suite.
Geography
This edition provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Where are the largest and fastest-growing opportunities within the GI endoscopic device market.
How screening programs and aging demographics will shape demand for colonoscopy and therapeutic endoscopy.
Which technology upgrades will gain share, including single-use platforms, AI-assisted tools, and advanced imaging.
How GPOs and tender models affect pricing and market access for both large and small manufacturers.
What procedure shifts are expected across ERCP, EUS, ESD, and capsule endoscopy, and how these affect accessory consumption.
How Olympus, Boston Scientific, and Fujifilm are positioned across capital and accessory segments.
What risks could slow adoption, including budget limits, screening alternatives, and clinician hesitancy.
How suppliers can align training, service, and inventory to support growth in emerging regions.
The Global Gastrointestinal Endoscopic Device Market Report from iData Research answers these questions with procedure-aware models, pricing detail, and company share analysis. Use it to quantify demand by category, plan product roadmaps, set pricing and contracting targets, and prioritize training and support programs that speed adoption.
Table Of Contents
List Of Figures
List Of Charts
Global Gastrointestinal Endoscopic Device Market Overview
Competitive Analysis
Emerging Markets And Technologies
Market Trends
Market Developments
Procedure Segmentation
Market Segmentation
Regions Included
Key Report Updates
Version History
Research Methodology
Impact Of Global Tariffs
Global Gastrointestinal Endoscopic Device Market Overview
Gastrointestinal Endoscope Market
Capsule Endoscopy Market
Stenting & Dilation Market
Endoscopic Retrograde Cholangiopancreatography Device Market
Biopsy Forceps And Polypectomy Snares Market
Eus Needle Market
Endoscopic Submucosal Dissection Knife Market
Hemostasis Device Market
Enteral Feeding Device Market
Anti-Reflux Device Market